INT155346

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.21
First Reported 2006
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 4
Disease Relevance 1.34
Pain Relevance 1.23

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Prkaca) Golgi apparatus (Prkaca) plasma membrane (Prkaca)
nucleus (Prkaca) protein complex (Prkaca) kinase activity (Prkaca)
Prkaca (Mus musculus)
Pain Link Frequency Relevance Heat
fluoxetine 8 99.66 Very High Very High Very High
antagonist 56 99.64 Very High Very High Very High
agonist 11 89.16 High High
Clonidine 1 83.88 Quite High
depression 2 72.88 Quite High
Central nervous system 1 59.48 Quite High
Glutamate 16 5.00 Very Low Very Low Very Low
imagery 8 5.00 Very Low Very Low Very Low
Inflammation 3 5.00 Very Low Very Low Very Low
Neuropeptide 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Stress 7 100.00 Very High Very High Very High
Targeted Disruption 3 84.60 Quite High
Depression 3 83.32 Quite High
Neurodegenerative Disease 5 79.84 Quite High
Reprotox - General 1 2 10.56 Low Low
Endometriosis (extended) 8 7.20 Low Low
Adenocarcinoma 9 5.00 Very Low Very Low Very Low
Cancer 7 5.00 Very Low Very Low Very Low
Ganglion Cysts 6 5.00 Very Low Very Low Very Low
INFLAMMATION 3 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Fluoxetine treatment could reverse CMS-induced inhibition of PKA activity and ERK1/2 phosphorylation in both genotypes.
Negative_regulation (reverse) of Negative_regulation (inhibition) of PKA associated with stress and fluoxetine
1) Confidence 0.21 Published 2009 Journal Neuropsychopharmacology Section Abstract Doc Link 18923397 Disease Relevance 1.34 Pain Relevance 0.72
These results suggest that the decrease in FD-40 transport would be mainly attributed to the decrease in intracellular cAMP and subsequent decrease in PKA activity via alpha(2)-receptor stimulation.
Negative_regulation (decrease) of Negative_regulation (decrease) of PKA
2) Confidence 0.08 Published 2009 Journal Int J Pharm Section Abstract Doc Link 18977284 Disease Relevance 0 Pain Relevance 0.25
By itself, application of the PKA inhibitor, H89 (20 ?
Negative_regulation (application) of Negative_regulation (inhibitor) of PKA
3) Confidence 0.06 Published 2006 Journal BMC Neurosci Section Body Doc Link PMC1388226 Disease Relevance 0 Pain Relevance 0.08
in the presence/absence of the FP receptor antagonist (AL8810), EP2 receptor antagonist (AH6809), EP4 receptor antagonist (ONOAE2227), PLC inhibitor (U73122), PKA inhibitor (4C3MQ), PKC inhibitor (GF109203x), EGFR kinase inhibitor (AG1478) or ERK1/2 inhibitor (PD98059) for 4 h.
Negative_regulation (inhibitor) of Negative_regulation (inhibitor) of PKA associated with antagonist
4) Confidence 0.04 Published 2008 Journal Molecular and Cellular Endocrinology Section Body Doc Link PMC2694994 Disease Relevance 0 Pain Relevance 0.18

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox